A PHASE 1, OPEN-LABEL STUDY IN HEALTHY PARTICIPANTS TO INVESTIGATE THE PHARMACOKINETICS OF RITLECITINIB FOLLOWING SINGLE ORAL ADMINISTRATION OF MODIFIED RELEASE FORMULATIONS UNDER FED AND FASTED CONDITIONS
Latest Information Update: 15 Apr 2025
At a glance
- Drugs Ritlecitinib (Primary)
- Indications Alopecia areata; Coeliac disease; Crohn's disease; Type 1 diabetes mellitus; Ulcerative colitis; Vitiligo
- Focus Pharmacokinetics
- Sponsors Pfizer
Most Recent Events
- 02 Apr 2024 Status changed from recruiting to completed.
- 19 Feb 2024 Planned End Date changed from 14 Mar 2024 to 5 Apr 2024.
- 19 Feb 2024 Planned primary completion date changed from 14 Mar 2024 to 5 Apr 2024.